|
|
|
European Pharmaceutical Contractor
|
We estimate that the total market for CROs grew by over 11% in 2002. This is not the spectacular 20% growth that we saw in the mid-1990s, but nonetheless it is a sign of a very healthy industry. The CRO market breaks down to US$5.56 billion for clinical research related activities (60%) and US$3.79 billion (40%) for preclinical toxicology and analysis - a grand total of US$9.39 billion. To put it another way, this is a market equal to the gross national product of Armenia, three times that of Zambia or more than the total health care expenditure of Finland.
It is still an industry dominated by relatively few large companies as Table 1 shows. Using the figures in Table 1 we calculate that the top 30 companies represent 64% of the total market; of these some 10 were private companies but these represented only 12% of the revenues of this group. Thus the 20 largest public companies account for 56% of the total market for CROs, while the top 10 private companies made up approximately 7.7% of the total.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
PHASE II & IIa Clinical Trials
21-22 February 2012, Lancaster London Hotel, London
Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >> |
|
 |
News and Press Releases |
 |
Delta Industrial Services to display at Pharmapack in France
Delta Industrial Services, a leader in web converting and packaging innovation, will be showcasing some of their recent developments in pharmaceutical manufacturing and pouching.
More info >> |
|
|
